Harrow
Open
$37.66
Prev. Close
$37.48
High
$37.75
Low
$37.55
Market Snapshot
$1.4B
-93.7
-0.49
$199.61M
373
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 373 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 373 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Recently from Cashu
Harrow Inc. Reports Mixed Q4 Results with Revenue Growth and Increased Operating Expenses
Harrow Inc. Addresses Mixed Fourth Quarter Results amid Growth Aspirations Harrow Inc. (NASDAQ:HROW) reports its fourth-quarter results, demonstrating a notable 42% increase in total revenue, totaling…
Harrow Health's Q4 Surge: 15% Revenue Growth and Continued Market Commitment
Harrow Health's Impressive Q4 Growth Signals Market Commitment Harrow Health showcases a robust performance in its fourth quarter, cementing its strategic position within the specialty pharmaceutical…
Harrow Reports Strong Q4 Growth, Positioned for Continued Success in Specialty Pharmaceuticals
Harrow's Innovative Growth in the Specialty Pharmaceuticals Sector Harrow (NASDAQ:HROW) reveals promising performance in its Q4 earnings report, showcasing a significant revenue growth of 15% year-ove…
Adapting to Market Volatility: Harrow's Strategic Focus in Economic Uncertainty
Navigating Market Volatility: Harrow's Strategic Focus Amid Economic Uncertainty As U.S. stock futures show a decline, the pharmaceutical sector, including companies like Harrow Health, remains alert…